Chan Mi Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chan Mi Park has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Dae Hyun Kim
Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts
13 shared publications Dae Hyun Kim
Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife , Harvard Medical School, Boston, Massachusetts
10 shared publications- Sandra Miao Shi
Frailty Research Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife , Boston, Massachusetts
8 shared publications - Ellen P. McCarthy
Frailty Research Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife , Boston, Massachusetts
7 shared publications Xiecheng Chen
Frailty Research Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife , Boston, Massachusetts
7 shared publications- Ga Eun Nam
Department of Family Medicine Korea University Guro Hospital Korea University College of Medicine Seoul Republic of Korea
5 shared publications
Latest Publications
- 19 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of Chronic Conditions Data Warehouse algorithms in Medicare Advantage and fee-for-service populations
Background: The Centers for Medicare & Medicaid Services (CMS) Chronic Conditions Data Warehouse (CCW) algorithms are widely used to identify chronic conditions in Medicare fee-for-service (FFS) claims. However, their validity in Medicare Advantage (MA) encounters remains uncertain. Methods: We conducted a cross-sectional study using the National Health and Aging Trends Study (NHATS) linked to Medicare data. We analyzed NHATS rounds 9 and 11, aged ≥ 65 years, with continuous 24-month enrollment in MA or FFS. Chronic Conditions Data Warehouse algorithms were applied to identify 6 conditions: arthritis, chronic lung disease, diabetes, heart disease, hypertension, and osteoporosis. Self-reported, physician-diagnosed conditions from NHATS interviews served as the reference standard. Survey-weighted sensitivity, specificity, positive predictive value (PPV), negative predictive value, and balanced accuracy were compared between MA and FFS. Results: We included 1708 MA and 2239 FFS beneficiaries in round 9 and 1472 MA and 1566 FFS beneficiaries in round 11. Across both rounds, balanced accuracy was similar between MA and FFS for all 6 conditions. Diabetes and hypertension demonstrated high sensitivity (0.88-0.94), while arthritis and osteoporosis showed lower sensitivity but high specificity. Although statistically significant MA–FFS differences were observed for select metrics (diabetes PPV in round 9; chronic lung disease specificity in round 11), absolute differences were minor and not clinically meaningful. Conclusions: Chronic Conditions Data Warehouse algorithms perform comparably in MA and FFS Medicare data. These findings support the validity of using CCW algorithms in MA encounter data for epidemiologic research for risk adjustment, facilitating more generalizable studies of the growing MA population.
- 19 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of Chronic Conditions Data Warehouse algorithms in Medicare Advantage and fee-for-service populations
Background: The Centers for Medicare & Medicaid Services (CMS) Chronic Conditions Data Warehouse (CCW) algorithms are widely used to identify chronic conditions in Medicare fee-for-service (FFS) claims. However, their validity in Medicare Advantage (MA) encounters remains uncertain. Methods: We conducted a cross-sectional study using the National Health and Aging Trends Study (NHATS) linked to Medicare data. We analyzed NHATS rounds 9 and 11, aged ≥ 65 years, with continuous 24-month enrollment in MA or FFS. Chronic Conditions Data Warehouse algorithms were applied to identify 6 conditions: arthritis, chronic lung disease, diabetes, heart disease, hypertension, and osteoporosis. Self-reported, physician-diagnosed conditions from NHATS interviews served as the reference standard. Survey-weighted sensitivity, specificity, positive predictive value (PPV), negative predictive value, and balanced accuracy were compared between MA and FFS. Results: We included 1708 MA and 2239 FFS beneficiaries in round 9 and 1472 MA and 1566 FFS beneficiaries in round 11. Across both rounds, balanced accuracy was similar between MA and FFS for all 6 conditions. Diabetes and hypertension demonstrated high sensitivity (0.88-0.94), while arthritis and osteoporosis showed lower sensitivity but high specificity. Although statistically significant MA–FFS differences were observed for select metrics (diabetes PPV in round 9; chronic lung disease specificity in round 11), absolute differences were minor and not clinically meaningful. Conclusions: Chronic Conditions Data Warehouse algorithms perform comparably in MA and FFS Medicare data. These findings support the validity of using CCW algorithms in MA encounter data for epidemiologic research for risk adjustment, facilitating more generalizable studies of the growing MA population.
- 18 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of claims-based Alzheimer’s disease and related dementias algorithms in Medicare Advantage and fee-for-service populations
Background: Evidence comparing the performance of claims-based dementia algorithms across Medicare Advantage (MA) and fee-for-service (FFS) populations remains limited. We evaluated the validity of 2 claims-based algorithms across MA and FFS populations. Methods: We used nationally representative, linked National Health and Aging Trends Study (NHATS)-Medicare data to identify community-dwelling participants with continuous enrollment in MA or FFS during Round 7 (2017; n = 5018), Round 9 (2019; n = 4018), and Round 11 (2021-2022; n = 3086). Using NHATS probable dementia as reference standard, we validated the Bynum-Standard and Chronic Condition Warehouse (CCW) dementia algorithms across 3-time points. Results: Overall, both algorithms demonstrated comparable performance in MA and FFS populations, with high specificity (>97.9%) and negative predictive value (>92.9%). The Bynum algorithm showed similar sensitivity between MA and FFS in Rounds 7 (30.2% vs 29.1%) and 11 (25.6% vs 23.9%), but lower sensitivity in MA for Round 9 (25.0% vs 36.4%). Positive predictive value (PPV) was similar between MA (62.7%-70.6%) and FFS (62.1%-70.4%) across all rounds. The CCW algorithm demonstrated greater MA-FFS differences, with lower sensitivity in MA for Rounds 9 (30.8% vs 46.9%) and 11 (35.0% vs 49.3%) and similar sensitivity for Round 7 (40.4% vs 42.2%). PPV varied across rounds in both MA and FFS ([Round 7: 76.3% vs 71.2%] to [Round 11: 68.5% vs 76.4%]). Both algorithms identified participants with more severe dementia. Conclusion: Claims-based dementia algorithms demonstrate broadly consistent performance in MA and FFS populations, with high specificity and moderate PPV but comparable or lower sensitivity in MA, informing case ascertainment across Medicare plan type.
- 18 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of claims-based Alzheimer’s disease and related dementias algorithms in Medicare Advantage and fee-for-service populations
Background: Evidence comparing the performance of claims-based dementia algorithms across Medicare Advantage (MA) and fee-for-service (FFS) populations remains limited. We evaluated the validity of 2 claims-based algorithms across MA and FFS populations. Methods: We used nationally representative, linked National Health and Aging Trends Study (NHATS)-Medicare data to identify community-dwelling participants with continuous enrollment in MA or FFS during Round 7 (2017; n = 5018), Round 9 (2019; n = 4018), and Round 11 (2021-2022; n = 3086). Using NHATS probable dementia as reference standard, we validated the Bynum-Standard and Chronic Condition Warehouse (CCW) dementia algorithms across 3-time points. Results: Overall, both algorithms demonstrated comparable performance in MA and FFS populations, with high specificity (>97.9%) and negative predictive value (>92.9%). The Bynum algorithm showed similar sensitivity between MA and FFS in Rounds 7 (30.2% vs 29.1%) and 11 (25.6% vs 23.9%), but lower sensitivity in MA for Round 9 (25.0% vs 36.4%). Positive predictive value (PPV) was similar between MA (62.7%-70.6%) and FFS (62.1%-70.4%) across all rounds. The CCW algorithm demonstrated greater MA-FFS differences, with lower sensitivity in MA for Rounds 9 (30.8% vs 46.9%) and 11 (35.0% vs 49.3%) and similar sensitivity for Round 7 (40.4% vs 42.2%). PPV varied across rounds in both MA and FFS ([Round 7: 76.3% vs 71.2%] to [Round 11: 68.5% vs 76.4%]). Both algorithms identified participants with more severe dementia. Conclusion: Claims-based dementia algorithms demonstrate broadly consistent performance in MA and FFS populations, with high specificity and moderate PPV but comparable or lower sensitivity in MA, informing case ascertainment across Medicare plan type.
- 18 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of claims-based frailty indices in Medicare Advantage and fee-for-service populations
Background: Despite growing enrollment in Medicare Advantage (MA) plans, the performance of claims-based frailty algorithms, which were developed for Medicare fee-for-service (FFS), remains unclear in MA. Methods: We calculated the Kim claims-based frailty index (CFI), Veterans Affairs-Frailty Index (VA-FI), and Hospital Frailty Risk Score (HFRS) using the National Health and Aging Trends Study linked to Medicare FFS and MA data. We evaluated their performance against the comprehensive geriatric assessment-based frailty index (CGA-FI) and the frailty phenotype (FP) in Round 11 and Round 9. Results: Among 1527 FFS and 1457 MA beneficiaries in Round 11, frailty prevalence was 34.2% and 35.5%, respectively, by CGA-FI ≥0.25, and 13.3% and 16.2%, respectively, by FP. Across FFS and MA populations, the CFI, which prioritizes specificity and positive predictive value, classified 10%-12% of the overall population and 30%-36% of those with prior hospitalization as frail, whereas the VA-FI and HFRS, which emphasize sensitivity, classified 53%-71% of the overall population and 56%-87% of those with prior hospitalization as frail. Although claims-based frailty measures performed similarly across FFS and MA populations, their discriminatory ability was higher for CGA-FI ≥0.25 (C-statistics: CFI, 0.79-0.82; VA-FI, 0.77-0.82; HFRS, 0.63-0.77) than for FP (CFI, 0.71-0.77; VA-FI, 0.67-0.75; HFRS, 0.60-0.74). Performance was consistent by race and survey rounds, with modestly better discrimination in women than men. Conclusions: Claims-based frailty measures are scalable tools for contemporary FFS and MA populations. However, applying published thresholds led to differences in frailty prevalence and model performance. Thresholds should therefore be tailored to the intended.
- 18 September 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (11)
Performance of claims-based frailty indices in Medicare Advantage and fee-for-service populations
Background: Despite growing enrollment in Medicare Advantage (MA) plans, the performance of claims-based frailty algorithms, which were developed for Medicare fee-for-service (FFS), remains unclear in MA. Methods: We calculated the Kim claims-based frailty index (CFI), Veterans Affairs-Frailty Index (VA-FI), and Hospital Frailty Risk Score (HFRS) using the National Health and Aging Trends Study linked to Medicare FFS and MA data. We evaluated their performance against the comprehensive geriatric assessment-based frailty index (CGA-FI) and the frailty phenotype (FP) in Round 11 and Round 9. Results: Among 1527 FFS and 1457 MA beneficiaries in Round 11, frailty prevalence was 34.2% and 35.5%, respectively, by CGA-FI ≥0.25, and 13.3% and 16.2%, respectively, by FP. Across FFS and MA populations, the CFI, which prioritizes specificity and positive predictive value, classified 10%-12% of the overall population and 30%-36% of those with prior hospitalization as frail, whereas the VA-FI and HFRS, which emphasize sensitivity, classified 53%-71% of the overall population and 56%-87% of those with prior hospitalization as frail. Although claims-based frailty measures performed similarly across FFS and MA populations, their discriminatory ability was higher for CGA-FI ≥0.25 (C-statistics: CFI, 0.79-0.82; VA-FI, 0.77-0.82; HFRS, 0.63-0.77) than for FP (CFI, 0.71-0.77; VA-FI, 0.67-0.75; HFRS, 0.60-0.74). Performance was consistent by race and survey rounds, with modestly better discrimination in women than men. Conclusions: Claims-based frailty measures are scalable tools for contemporary FFS and MA populations. However, applying published thresholds led to differences in frailty prevalence and model performance. Thresholds should therefore be tailored to the intended.
- 2 July 2026
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 27 (8) , 106350
Clinician-Reported DMARD Disruption During Skilled Nursing Facility Transitions Among Older Adults With Rheumatic Diseases
- 2 July 2026
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 27 (8) , 106350
Clinician-Reported DMARD Disruption During Skilled Nursing Facility Transitions Among Older Adults With Rheumatic Diseases
- 2 June 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (7)
Frailty and the efficacy and safety of surgical versus endovascular revascularization: post-hoc analysis of the BEST-CLI trial
Background: Frailty is associated with mortality and adverse outcomes in chronic limb-threatening ischaemia (CLTI). Although prompt revascularization is recommended to reduce major adverse limb events (MALE), it is unclear whether frailty modifies the relative effectiveness of surgical versus endovascular therapy. The aim of this study was to assess whether the outcomes of these strategies differ by frailty status in the BEST-CLI randomized trial. Methods: A frailty index (FI; 0–1) was constructed using a deficit-accumulation approach; severe frailty was defined as an FI ≥0.45. The primary endpoint was MALE or death, and the safety endpoint was major adverse cardiovascular events (MACE). Patients with an adequate great saphenous vein (GSV) (cohort 1) and those requiring an alternative conduit (cohort 2) were analysed separately. Results: Of 1830 randomized patients, the FI was calculable for 1754 patients. Severe frailty was present in 654 patients (47.6%) in cohort 1 and 187 patients (49.3%) in cohort 2 and was associated with higher MALE or death regardless of treatment. In cohort 1, surgical bypass reduced the risk of MALE or death in both severely frail patients (51.0% versus 67.2%; HR 0.68 (95% c.i. 0.55 to 0.83)) and non-severely frail patients (35.4% versus 48.2%; HR 0.68 (95% c.i. 0.54 to 0.86)) versus endovascular therapy (interaction P = 0.95). In cohort 2, outcomes were similar between treatment groups across frailty strata. No interaction was observed between frailty and treatment strategy for MACE. Conclusion: In the BEST-CLI trial, severe frailty was associated with higher MALE or death. Among patients suitable for bypass with an adequate GSV, surgical bypass was more effective than endovascular therapy irrespective of frailty status.
- 2 June 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (7)
Frailty and the efficacy and safety of surgical versus endovascular revascularization: post-hoc analysis of the BEST-CLI trial
Background: Frailty is associated with mortality and adverse outcomes in chronic limb-threatening ischaemia (CLTI). Although prompt revascularization is recommended to reduce major adverse limb events (MALE), it is unclear whether frailty modifies the relative effectiveness of surgical versus endovascular therapy. The aim of this study was to assess whether the outcomes of these strategies differ by frailty status in the BEST-CLI randomized trial. Methods: A frailty index (FI; 0–1) was constructed using a deficit-accumulation approach; severe frailty was defined as an FI ≥0.45. The primary endpoint was MALE or death, and the safety endpoint was major adverse cardiovascular events (MACE). Patients with an adequate great saphenous vein (GSV) (cohort 1) and those requiring an alternative conduit (cohort 2) were analysed separately. Results: Of 1830 randomized patients, the FI was calculable for 1754 patients. Severe frailty was present in 654 patients (47.6%) in cohort 1 and 187 patients (49.3%) in cohort 2 and was associated with higher MALE or death regardless of treatment. In cohort 1, surgical bypass reduced the risk of MALE or death in both severely frail patients (51.0% versus 67.2%; HR 0.68 (95% c.i. 0.55 to 0.83)) and non-severely frail patients (35.4% versus 48.2%; HR 0.68 (95% c.i. 0.54 to 0.86)) versus endovascular therapy (interaction P = 0.95). In cohort 2, outcomes were similar between treatment groups across frailty strata. No interaction was observed between frailty and treatment strategy for MACE. Conclusion: In the BEST-CLI trial, severe frailty was associated with higher MALE or death. Among patients suitable for bypass with an adequate GSV, surgical bypass was more effective than endovascular therapy irrespective of frailty status.
- 21 May 2026
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 66 (7)
Social determinants of health and utilization of transitional and chronic care management services among Medicare beneficiaries: a case-control study
Background and Objectives: The Centers for Medicare & Medicaid Services launched transitional care management (TCM) and chronic care management (CCM) services to improve care coordination. However, the social determinants of health (SDOH) that affect access to these services remain poorly understood. Research Design and Methods: We included Medicare Current Beneficiary Survey participants from 2016 to 2020. 6 SDOH domains: Economic stability; Social support and community; Healthcare access; Transportation; Education; and Neighborhood environment were measured. We performed a conditional logistic regression to model receipt of TCM or CCM as a function of the 6 SDOH domains and covariates. Results: 682 TCM cases were matched to 1,364 controls, and 362 CCM cases were matched to 724 controls. Compared to controls, TCM recipients were older (mean [SD] age, 76.3 [SD 10.9] vs 70.9 [13.2] years), as were CCM recipients (74.4 [10.5] vs 73.2 [10.6] years). Greater social disadvantage was associated with lower odds of TCM receipt. Specifically, poorer healthcare access (tertile 2 vs 0: OR 0.61, 95% CI 0.42–0.88) and rural residence (OR 0.48, 95% CI 0.34–0.68) were associated with reduced TCM use. In contrast, greater economic instability (per 1−SD increase: OR 1.16, 95% CI 0.97–1.38) and transportation barriers (OR 1.16, 95% CI 0.99–1.36) were associated with higher odds of CCM use. Discussion and Implications: SDOH has divergent associations with TCM and CCM utilization, revealing potential inequities in access to timely post-discharge care, with CCM may be reaching more socially vulnerable individuals.
- 21 May 2026
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 66 (7)
Social determinants of health and utilization of transitional and chronic care management services among Medicare beneficiaries: a case-control study
Background and Objectives: The Centers for Medicare & Medicaid Services launched transitional care management (TCM) and chronic care management (CCM) services to improve care coordination. However, the social determinants of health (SDOH) that affect access to these services remain poorly understood. Research Design and Methods: We included Medicare Current Beneficiary Survey participants from 2016 to 2020. 6 SDOH domains: Economic stability; Social support and community; Healthcare access; Transportation; Education; and Neighborhood environment were measured. We performed a conditional logistic regression to model receipt of TCM or CCM as a function of the 6 SDOH domains and covariates. Results: 682 TCM cases were matched to 1,364 controls, and 362 CCM cases were matched to 724 controls. Compared to controls, TCM recipients were older (mean [SD] age, 76.3 [SD 10.9] vs 70.9 [13.2] years), as were CCM recipients (74.4 [10.5] vs 73.2 [10.6] years). Greater social disadvantage was associated with lower odds of TCM receipt. Specifically, poorer healthcare access (tertile 2 vs 0: OR 0.61, 95% CI 0.42–0.88) and rural residence (OR 0.48, 95% CI 0.34–0.68) were associated with reduced TCM use. In contrast, greater economic instability (per 1−SD increase: OR 1.16, 95% CI 0.97–1.38) and transportation barriers (OR 1.16, 95% CI 0.99–1.36) were associated with higher odds of CCM use. Discussion and Implications: SDOH has divergent associations with TCM and CCM utilization, revealing potential inequities in access to timely post-discharge care, with CCM may be reaching more socially vulnerable individuals.
- 26 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1362-1373
Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism in Frail and Non‐Frail Older Adults
In this retrospective cohort of 18 066 Medicare fee‐for‐service beneficiaries ≥ 65 years with acute VTE (2015–2019), we compared apixaban, rivaroxaban, and warfarin using propensity score (PS) overlap weighting and intention‐to‐treat analyses across total, non‐frail, and frail strata defined by a claims‐based frailty index. After PS weighting (all SMDs < 0.10), apixaban versus warfarin was associated with a lower 1‐year composite of recurrent VTE or death in the total population (189.1 versus 216.1 per 1000 PY; HR 0.86, 95% CI 0.77–0.96), with benefit evident in non‐frail patients (114.5 versus 143.6; HR 0.78, 0.66–0.92) and attenuated in frail patients (330.9 versus 349.9; HR 0.93, 0.82–1.07). Recurrent VTE rates favored apixaban but were not statistically significant overall (40.5 versus 54.8; HR 0.86, 0.68–1.08). Major bleeding was lower with apixaban (19.4 versus 26.0; HR 0.73, 0.53–1.00). Home‐time loss was reduced with apixaban compared with warfarin in the total population (mean 54.9 versus 67.0 days; RR 0.89, 0.83–0.96) and was directionally similar across both frailty strata. Rivaroxaban showed no clear advantage over warfarin for the composite (216.9 versus 216.1; HR 1.00, 0.90–1.11) or bleeding (HR 0.99, 0.73–1.32) and yielded greater home‐time loss than apixaban (RR 1.08, 1.01–1.17). Overall, apixaban demonstrated the most favorable balance of effectiveness, safety, and patient‐centered benefit, with patterns generally consistent across frailty levels.
- 26 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1362-1373
Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism in Frail and Non‐Frail Older Adults
In this retrospective cohort of 18 066 Medicare fee‐for‐service beneficiaries ≥ 65 years with acute VTE (2015–2019), we compared apixaban, rivaroxaban, and warfarin using propensity score (PS) overlap weighting and intention‐to‐treat analyses across total, non‐frail, and frail strata defined by a claims‐based frailty index. After PS weighting (all SMDs < 0.10), apixaban versus warfarin was associated with a lower 1‐year composite of recurrent VTE or death in the total population (189.1 versus 216.1 per 1000 PY; HR 0.86, 95% CI 0.77–0.96), with benefit evident in non‐frail patients (114.5 versus 143.6; HR 0.78, 0.66–0.92) and attenuated in frail patients (330.9 versus 349.9; HR 0.93, 0.82–1.07). Recurrent VTE rates favored apixaban but were not statistically significant overall (40.5 versus 54.8; HR 0.86, 0.68–1.08). Major bleeding was lower with apixaban (19.4 versus 26.0; HR 0.73, 0.53–1.00). Home‐time loss was reduced with apixaban compared with warfarin in the total population (mean 54.9 versus 67.0 days; RR 0.89, 0.83–0.96) and was directionally similar across both frailty strata. Rivaroxaban showed no clear advantage over warfarin for the composite (216.9 versus 216.1; HR 1.00, 0.90–1.11) or bleeding (HR 0.99, 0.73–1.32) and yielded greater home‐time loss than apixaban (RR 1.08, 1.01–1.17). Overall, apixaban demonstrated the most favorable balance of effectiveness, safety, and patient‐centered benefit, with patterns generally consistent across frailty levels.
- Open Access
- 20 March 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (4) , e75-e76
Response to Comment on Park et al. Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. Diabetes Care 2026;49:147–151
We thank Maltese and Sinclair (1) for their thoughtful comments on our article that was recently published in Diabetes Care (2). We appreciate the opportun
- 20 March 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (4) , e75-e76
Open AccessResponse to Comment on Park et al. Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. Diabetes Care 2026;49:147–151
We thank Maltese and Sinclair (1) for their thoughtful comments on our article that was recently published in Diabetes Care (2). We appreciate the opportun
- 13 November 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (1) , 147-151
Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes
OBJECTIVE: Older adults with type 2 diabetes are at high risk for frailty. The effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT-2is) on frailty remain uncertain. RESEARCH DESIGN AND METHODS: Using a 7% random sample of Medicare data, we compared new users of dipeptidyl peptidase 4 inhibitors (DPP-4is), GLP-1RAs, SGLT-2is, and sulfonylureas on 1-year frailty progression, measured by a claims-based frailty index (CFI) (range: 0–1; higher scores indicate greater frailty). Mediation analyses assessed whether cardiovascular or safety events explained differences in frailty progression. RESULTS: Compared with DPP-4i users, the mean CFI change (95% CI) was significantly lower for GLP-1RA (−0.007 [−0.011, −0.004]) and SGLT-2i (−0.005 [−0.008, −0.002]) users; no difference was found for sulfonylurea users. These associations were minimally mediated by cardiovascular or safety events. CONCLUSIONS: GLP-1RAs and SGLT-2is may slow frailty progression through mechanisms independent of cardiovascular benefits. Future trials should confirm these preliminary findings.
- 13 November 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (1) , 147-151
Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes
OBJECTIVE: Older adults with type 2 diabetes are at high risk for frailty. The effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT-2is) on frailty remain uncertain. RESEARCH DESIGN AND METHODS: Using a 7% random sample of Medicare data, we compared new users of dipeptidyl peptidase 4 inhibitors (DPP-4is), GLP-1RAs, SGLT-2is, and sulfonylureas on 1-year frailty progression, measured by a claims-based frailty index (CFI) (range: 0–1; higher scores indicate greater frailty). Mediation analyses assessed whether cardiovascular or safety events explained differences in frailty progression. RESULTS: Compared with DPP-4i users, the mean CFI change (95% CI) was significantly lower for GLP-1RA (−0.007 [−0.011, −0.004]) and SGLT-2i (−0.005 [−0.008, −0.002]) users; no difference was found for sulfonylurea users. These associations were minimally mediated by cardiovascular or safety events. CONCLUSIONS: GLP-1RAs and SGLT-2is may slow frailty progression through mechanisms independent of cardiovascular benefits. Future trials should confirm these preliminary findings.
- 29 September 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (12)
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Background: Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods: To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results: Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion: Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.
- 29 September 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (12)
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Background: Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods: To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results: Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion: Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.